Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Gt Biopharma Inc. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners, which means each pending matter is under the review of a different individual. Despite having multiple examiners involved, the work is concentrated within 1 distinct art unit, suggesting that the technical subject matter of the applications is closely related and falls under a unified set of examination guidelines.
The busiest examiner for the portfolio is AUDREY L BUTTICE, who is responsible for a pending office action. With a busiest examiner pending count of 1, the workload is split across the distinct examiners. The presence of 2 pending office actions indicates an active pipeline of intellectual property development in the biotechnology sector. Maintaining a presence in the art unit allows the company to develop a deep understanding of the specific examination trends relevant to its pharmaceutical research.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
| SUNSHINE, HANNAH LOUISE | 1 | 62.5% | +24.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641594 | IMMUNOTHERAPY COMPOUNDS AND METHODS | SUNSHINE, HANNAH LOUISE | 3d overdue |
| 18692775 | PD-L1 TARGETING FUSION PROTEINS AND METHODS OF USE THEREOF | BUTTICE, AUDREY L | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692775 | PD-L1 TARGETING FUSION PROTEINS AND METHODS OF USE THEREOF | BUTTICE, AUDREY L | — | §102§103§112DP | Non-Final OA | — | Pending | Mar 15, 2024 |
| 17641594 | IMMUNOTHERAPY COMPOUNDS AND METHODS | SUNSHINE, HANNAH LOUISE | 1647 | §103DP | Non-Final OA | 3d overdue | Pending | Mar 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial